Targeting Notch in oncology: the path forward.

TitleTargeting Notch in oncology: the path forward.
Publication TypeJournal Article
Year of Publication2021
AuthorsMajumder, S, Crabtree, JS, Golde, TE, Minter, LM, Osborne, BA, Miele, L
JournalNat Rev Drug Discov
Date Published2021 02
KeywordsAnimals, Antineoplastic Agents, Drug Delivery Systems, Humans, Immunotherapy, Neoplasms, Neoplastic Stem Cells, Receptors, Notch, Signal Transduction

Notch signalling is involved in many aspects of cancer biology, including angiogenesis, tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can function as an oncogene and a tumour suppressor in different cancers and in different cell populations within the same tumour. Despite promising preclinical results and early-phase clinical trials, the goal of developing safe, effective, tumour-selective Notch-targeting agents for clinical use remains elusive. However, our continually improving understanding of Notch signalling in specific cancers, individual cancer cases and different cell populations, as well as crosstalk between pathways, is aiding the discovery and development of novel investigational Notch-targeted therapeutics.

Alternate JournalNat Rev Drug Discov
PubMed ID33293690
Grant ListU54 GM104940 / GM / NIGMS NIH HHS / United States